Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

During the Combination Therapy Period, the safety and preliminary anti-tumor activity of selinexor in combination with docetaxel (for patients with NSCLC) or pembrolizumab (for patients with CRC) will be evaluated.

measurable disease
liver function tests
gilbert's syndrome
docetaxel
metastatic nsclc
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

A tolerable safety profile and demonstrated efficacy would support a potential, randomized phase 3 trial comparing the experimental combination therapy and standard of care intravesical BCG therapy.

hormone level
intravesical bcg
follicle stimulating hormone
bladder carcinoma
docetaxel
  • 0 views
  • 19 Feb, 2024
  • 1 location
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation

The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity. Irradiation is applied - significantly shorter than the combination therapy - in about 4 weeks (22 fractions); …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Combination Immunotherapy Targeting Sarcomas

The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines …

recurrent sarcoma
immunosuppression
sarcoma
immunosuppressive agents
serum bilirubin level
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

axillary lymph node dissection
immunohistochemistry
mastectomy
serum bilirubin
serum bilirubin level
  • 0 views
  • 19 Feb, 2024
  • 1 location